[Edaily Reporter Kwon Oh Seok ] #G2GBIO, Inc. announced on the 27th that it had received the draft Clinical Study Report (CSR) for the Phase 1 clinical trial of “GB-5001,” a long-acting dementia treatment administered once a month. According to the company, this Phase 1 clinical trial was conducted to evaluate the safety and tolerability of GB-5001 following both single and repeated doses. The company stated, “In conclusion, no serious adverse events (SAEs) were reported in terms of safety, and most adverse events (AEs) were confirmed to be mild,” adding, “There was no significant difference in the impact of increasing the dose on safety. "Furthermore, tolerability was generally excellent, and the doses administered (70 mg, 140 mg, and 280 mg) were deemed to be within a safe range," the company explained.